## EQR: Equity Residential - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_20 0.5% below STRENGTH zone (4.0-10.0%); PEG 8.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($60.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Sarasin & Partners LLP Decreases Position in Equity Residential $EQR**
- Source: MarketBeat | 20251221T124706 | Neutral | Relevance: 100%
- Sarasin & Partners LLP significantly reduced its stake in Equity Residential (NYSE:EQR) by 65% in Q3, selling 60,094 shares and retaining 32,408 shares valued at approximately $2.08 million. Despite this reduction, Equity Residential reported Q3 EPS in line with estimates, provided optimistic Q4 and FY2025 guidance, and declared a quarterly dividend of $0.6925. The company's stock shows a market cap of $23.39 billion with a dividend yield of 4.5%, and institutional investors collectively own 92.68% of its shares.

**2. How Investors May Respond To Regency Centers (REG) Adding Equity Residential CEO Mark Parrell To Its Board**
- Source: Simply Wall Street | 20251222T060859 | Neutral | Relevance: 70%
- Regency Centers (REG) has announced the appointment of Mark J. Parrell, President and CEO of Equity Residential, to its Board of Directors, effective January 1, 2026. This move expands the board to twelve members and places Parrell on the Audit and Investment committees, aiming to leverage his extensive real estate and capital allocation expertise. While seen as a governance positive, the article suggests it's an incremental rather than a near-term catalyst and emphasizes that investors should continue to focus on Regency's dividend policy and the financial implications of its development-heavy growth strategy.

**3. How Investors May Respond To Regency Centers (REG) Adding Equity Residential CEO Mark Parrell To Its Board**
- Source: Simply Wall Street | 20251221T234032 | Neutral | Relevance: 64%
- Regency Centers (REG) has appointed Mark J. Parrell, CEO of Equity Residential, to its Board of Directors, expanding it to twelve members and giving him roles on the Audit and Investment committees. This move is seen as an incremental governance positive, bringing expertise in real estate and capital allocation, but it doesn't fundamentally alter the investment narrative or risks associated with development-heavy growth. Investors should watch how Regency balances its recent dividend increase with its substantial development pipeline, especially concerning potential rising costs or tighter capital markets.

**4. Camden Property Trust (CPT): Reassessing Valuation After Dual Listing, 2025 Guidance Upgrade and JP Morgan Rating Boost**
- Source: Simply Wall Street | 20251221T182947 | Neutral | Relevance: 63%
- Camden Property Trust (CPT) experienced three recent positive catalysts: a new NYSE Texas dual listing, upgraded 2025 guidance, and a JP Morgan rating increase, influencing investor perception. Despite a negative year-to-date share price return, its five-year total shareholder return indicates long-term momentum. The stock is considered 8.1% undervalued with a fair value of $116.67, driven by operating efficiency and capital management, though valuation models show it trading higher than peers based on its P/E ratio.

**5. How Investors May Respond To Regency Centers (REG) Adding Equity Residential CEO Mark Parrell To Its Board**
- Source: Sahm | 20251222T210822 | Neutral | Relevance: 63%
- Regency Centers (REG) has elected Mark J. Parrell, President and CEO of Equity Residential, to its Board of Directors, effective January 1, 2026. This addition is viewed as a governance positive, bringing real estate and capital allocation expertise to the board, and reinforces the company's focus on distributing a growing income stream alongside its development pipeline. While not a near-term catalyst, investors should consider the implications for Regency's dividend strategy and project risks as it balances cash returns with future growth commitments.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | Barclays | $77 | $80 | -4% |
| 2025-11-24 | Mizuho | $65 | $66 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | Barclays | main | Overweight |
| 2025-11-24 | Mizuho | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 15.1% (+2.3%)
- Blackrock Inc.: 10.2% (+1.1%)
- State Street Corpora: 6.6% (+2.8%)
- Price (T.Rowe) Assoc: 5.2% (-4.5%)
- Apg Asset Management: 3.0% (-0.7%)

### Key Risks

1. Valuation stretched: PEG 8.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 8.15 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 38%). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.5B |
| Beta | 0.76 |
| 52W Range | $58.38 - $75.86 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 8.15 |
| Forward P/E | 43.0 |
| Current P/E | 34.8 |
| YoY Growth | -19.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.8% to 0.5% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 59. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.53% (CS: 61) | Neutral |
| RSI_14 | 58.9 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.023x | Above |
| vs SMA200 | 0.951x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $62.32
- **Stop Loss:** $60.28 (3.3% risk)
- **Target:** $64.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 294
- **Position Value:** $18,322.08
- **Portfolio %:** 18.32%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $0.38)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.37 | -11.5% |
| 2025Q2 | $0.30 | $0.34 | +12.6% |
| 2025Q1 | $0.27 | $0.26 | -4.9% |
| 2024Q4 | $0.40 | $0.26 | -35.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*